NanoFlu investigational vaccine

Seasonal influenza Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
Seasonal influenza
 
Phase 3
Matrix-M™ adjuvant
Therapeutic area
Respiratory diseases
Infectious disease
Seasonal influenza
Status
 
Phase 3
Technology
Matrix-M™ adjuvant

About the candidate

NanoFlu is our quadrivalent nanoparticle influenza vaccine (qNIV) candidate, targeting seasonal flu. NanoFlu is designed using our recombinant technology, with 4 forms of wild-type hemagglutinin (HA) protein from the influenza virus as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.

Why it matters

Seasonal influenza is a significant global burden, with up to 650,000 flu-related deaths each year around the world.1 Current influenza vaccines have several limitations.2 A new generation of vaccines is needed to offer protection from disease.

In a successful phase 3 trial in the United States, NanoFlu met all of its endpoints.3

  1. Influenza – estimating burden of disease. WHO. Available at: https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza [Accessed 3 Sept 2021].
  2. Soema P, et al. Eur J Biopharm. 2015;95:251–263.
  3. Shinde V, et al. Lancet Infect Dis. Sept 2021. doi: https://doi.org/10.1016/S1473-3099(21)00192-4. [Accessed 2 Feb 2022]